Yiran Ao

Harvesting autologous soft tissue from the hard palate is a standard procedure, but managing the donor site wound is critical for patient comfort and reducing complications. Traditional methods like palatal stents are often costly and uncomfortable. While commercially available mucoadhesive bandages offer a barrier, their adhesion alone is temporary and unreliable, often failing prematurely due to oral movements. A novel "palatal shield" technique using composite resin stabilized on adjacent teeth's palatal surface has been proposed to address postoperative discomfort, yet it still has limitations in adaptability. This article and accompanying video demonstrate a comprehensive protocol that overcomes this limitation by combining a collagen sponge scaffold with a mucoadhesive bandage, which is then firmly secured using stabilizing suspension sutures. The key protocol steps include: (1) placing a collagen sponge into the donor site after initial hemostasis; (2) applying the trimmed mucoadhesive bandage to cover the sponge and overlap onto the peripheral dry mucosa; and (3) firmly securing the entire dressing using crossed horizontal mattress suspension sutures. This multi-layer system creates a stable, long-lasting physical barrier that protects the underlying wound from mechanical irritation and bacterial contamination, addressing the issue of donor site morbidities such as postoperative bleeding and pain that plague both clinicians and patients. This method provides immediate hemostasis, significantly reduces postoperative pain, and promotes predictable, advanced healing. Compared to novel palatal stents made of light-curing hybrid composite resin, where some patients report speaking inconvenience, this protocol avoids such functional disruptions. Additionally, it eliminates the need for extra fabrication steps required by transparent palatal plates used in combination with artificial dermis. This protocol provides a reliable, cost-effective, and reproducible technique that enhances patient comfort and optimizes palatal donor site healing.

Harvesting autologous soft tissue from the hard palate is a standard procedure, but managing the donor site wound is critical for patient comfort and reducing complications. Traditional methods like palatal stents are often costly and uncomfortable. While commercially available mucoadhesive bandages offer a barrier, their adhesion alone is temporary and unreliable, often failing prematurely due to oral movements. A novel "palatal shield" technique using composite resin stabilized on adjacent teeth's palatal surface has been proposed to address postoperative discomfort, yet it still has limitations in adaptability. This article and accompanying video demonstrate a comprehensive protocol that overcomes this limitation by combining a collagen sponge scaffold with a mucoadhesive bandage, which is then firmly secured using stabilizing suspension sutures. The key protocol steps include: (1) placing a collagen sponge into the donor site after initial hemostasis; (2) applying the trimmed mucoadhesive bandage to cover the sponge and overlap onto the peripheral dry mucosa; and (3) firmly securing the entire dressing using crossed horizontal mattress suspension sutures. This multi-layer system creates a stable, long-lasting physical barrier that protects the underlying wound from mechanical irritation and bacterial contamination, addressing the issue of donor site morbidities such as postoperative bleeding and pain that plague both clinicians and patients. This method provides immediate hemostasis, significantly reduces postoperative pain, and promotes predictable, advanced healing. Compared to novel palatal stents made of light-curing hybrid composite resin, where some patients report speaking inconvenience, this protocol avoids such functional disruptions. Additionally, it eliminates the need for extra fabrication steps required by transparent palatal plates used in combination with artificial dermis. This protocol provides a reliable, cost-effective, and reproducible technique that enhances patient comfort and optimizes palatal donor site healing.

In recent decades, immunotherapy has been considered a promising treatment approach. The modulatable enhancement or attenuation of the body’s immune response can effectively suppress tumors. However, challenges persist in clinical applications due to the lack of precision in antigen presentation to immune cells, immune escape mechanisms, and immunotherapy-mediated side effects. As a potential delivery system for drugs and immunomodulators, mesoporous silica has attracted extensive attention recently. Mesoporous silica nanoparticles (MSNs) possess high porosity, a large specific surface area, excellent biocompatibility, and facile surface modifiability, making them suitable as multifunctional carriers in immunotherapy. This article summarizes the latest advancements in the application of MSNs as carriers in cancer immunotherapy, aiming to stimulate further exploration of the immunomodulatory mechanisms and the development of immunotherapeutics based on MSNs.

Glioblastoma multiforme (GBM) is the most aggressive and common adult brain tumor. Current therapies primarily involve surgical resection, followed by chemotherapy and radiotherapy. However, the low survival rate due to high toxicity, side effects, and poor targeting necessitates novel treatments. Post‐transcriptional regulation pathways, particularly the regulation of alternative polyadenylation based on the mRNA 3′UTR, play a critical role in cell growth and development and the progression of tumors. Targeting tumor cells and reprogramming the 3′UTR of tumor suppressor genes to achieve post‐transcriptional regulation is expected to be a new channel for GBM therapy. Herein, a novel siRNA delivery system is developed based on mesoporous silica nanoparticles: siRNA composite nanoparticles (siRNA CNP). Encapsulation in MSNs overcomes siRNA degradation and cellular entry issues, while lipid bilayer coating improves biocompatibility and stability. Surface‐modified nucleic acid aptamer SL1 (Apt‐SL1) significantly enhances GBM targeting, offering therapeutic potential. The findings show that siRNA CNP effectively silences the promoter CFIm25 of distal poly(A) in tumor cells, inducing gene reprogramming, inhibiting tumor growth, and promoting apoptosis in nude mice. The siRNA CNP demonstrates a significant effect in reprogramming tumor suppressor genes and treating GBM. It offers a novel and promising therapeutic avenue for GBM.

The clock gene PER1 plays an important role in regulating the clock gene network in human oral squamous cell carcinoma cells The clock gene PER1 plays an important role in regulating the clock gene network in human oral squamous cell carcinoma cells